US$4.1bn

Capital Deployed

40+ years

Investing Experience

Active Value Creation

In partnership with our management teams, we combine operational change with introducing artificial intelligence and automation to drive value in each of our investments

Stanley Capital shares our vision to bring innovative technology solutions together with our high calibre medical and scientific resources as we strengthen our end-to-end client offering. Stanley brings technology expertise, deep sector understanding and M&A capability that will help us accelerate our future growth Humaira Qureshi, CEO of Qinecsa
With our strong base in the French market, we see tremendous opportunity for continued growth both in France and internationally. The management team and myself have been impressed by Stanley Capital’s vision for the business, their expertise and their connections in the pharmaceutical world. I am really excited to continue the development of LXO with Stanley Capital and I'm convinced that we will reach our common vision to reinforce our position as a robust pharma company specialized in acquiring and developing sales of established essential products for patients health, and perceived as a partner of choice by several big pharmas for their licensing-out options Karine Pinon, Founder of Laboratoire XO

Stanley Capital’s involvement in Noden Pharma has reinvigorated our business through unparalleled rigour in the development of our value creation plans, the value-add board of directors they have built around the business and have helped develop an origination approach to our platform M&A strategy not seen in any other investment firm
Alan Markey, CEO – Noden Pharma